Evaluation of the outcomes in patients with chronic myeloid leukemia treated with imatinib in 18-year follow-up

The objective of this paper is to examine the effects of Imatinib on patients who are at the chronic phase of chronic myeloid leukemia (CML). Method: Totally, 79 patients with CML who received the treatment between 2003 and 2020 entered the study. The patients were evaluated in terms of molecular re...

Descripción completa

Detalles Bibliográficos
Autores principales: Aznab, Mozafar, Shahriari-Ahmadi, Ali, Heydarpour, Fatemeh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8487986/
https://www.ncbi.nlm.nih.gov/pubmed/34631408
http://dx.doi.org/10.1016/j.lrr.2021.100271
Descripción
Sumario:The objective of this paper is to examine the effects of Imatinib on patients who are at the chronic phase of chronic myeloid leukemia (CML). Method: Totally, 79 patients with CML who received the treatment between 2003 and 2020 entered the study. The patients were evaluated in terms of molecular response rate and overall survival (OS). Results: About 75.9% of patients achieved deep molecular response in mean follow-up of 89.92 months. The OS rate was about 91.2%. Conclusion: There was no considerable cumulative toxicity with Imatinib long-term use. A high percent of patients had a deep molecular response.

Ejemplares similares